Search
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigationalOften, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12.
Pseudoephedrine
go.drugbank.com/drugs/DB00852ApprovedPseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.
Mixtures: Entex T, Pediatex TDCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigationalMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering … [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518]
Metacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Buprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedCombination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist … [A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: BUPRE-HEXAL 7 T 5 UG/H, BUPRE-HEXAL 4 T 35 UG/HPeramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.
Elapegademase
go.drugbank.com/drugs/DB14712Approved[F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]
Synonyms: -METHOXYPOLY(O, (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTEDTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalIt is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. … Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalThe ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents. … [A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015]